echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Alzheimer's dementia: BACE1 biomarkers predict Alzheimer's disease

    Alzheimer's dementia: BACE1 biomarkers predict Alzheimer's disease

    • Last Update: 2021-02-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    β amyloid prelocation protein cutting enzyme 1 (BACE1, also known as β-secretase) is a speed limit step in the amyloid protein production pathway.
    concentration and activity of THE PROTEIN1 protein in the brain of Alzheimer's disease (AD) increased compared to people with normal cognition.
    BACE1 is considered an early promising therapeutic target for AD, so different BACE1 inhibitors have been studied.
    same time, translation studies have shown that BACE1 activity is also a major determinant of synactical remodeling and plasticity through amyloid or non-amyloid pathogens.
    to better understand the overall effects of BACE1 on synapses, especially in the early stages of AD, seems useful for optimizing the integration of BACE1 biomarkers in pharmacological trials against BACE1.
    measurements of cerebrospinal fluid (CSF) BACE1, including concentration and enzyme activity, provide a valid candidate biomarker for AD in different contexts of use.
    Over the past 15 years, a number of in vivo studies have reported good diagnostic performance of CSF BACE1 protein concentrations (reflecting gene expression levels) and activity in distinguishing AD dementia (ADD), mild cognitive impairment (MCI), and cognitive health individuals.
    BACE1 biomarkers are associated with core biomarkers in AD CSF and neuroimaging.
    , the BACE1 biomarker performs significantly in predicting progression from MCI to AD dementia.
    , however, studies of blood-based BACE1 biomarkers in pre-drive/clinical AD individuals or cognitively healthy older adults at risk of AD remain limited.
    the evidence currently available, there is a good correspondence between CSF and plasma BACE1 concentrations.
    addition, plasma BACE1 activity can distinguish AD dementia patients from MCI and cognitively normal people, and predict the transformation from MCI to ADD.
    , Andrea Vergallo of the University of Sorbonne in France and others, based on the INSIGHT-preAD research team, explored the relationship between plasma BACE1 and neurodegenerative and synth-lost neuroimaging student markers.
    they used magnetic resonance imaging (MRI) to quantify regional brain volume and analyzed the metabolic activity of a priori selected brain regions that are usually affected in the early stages of AD using 18F-fluorodesic glucose-PET (18FFDG-PET).
    , it was also studied whether BACE1 protein concentration could predict cognitive decline in 3 years of follow-up.
    results show that, vertically, THERE is a positive correlation between BACE1 and NfL and t-tau, and a correlation between the annual change in BACE1 and the bienn yearly decrease in the volume of the fore brain.
    and there is a positive correlation between BACE1 and the baseline FDG-PET signal.
    importance of this study is that there is a positive correlation between BACE1 and FDG-PET signals on the baseline.
    link between plasma BACE1 protein concentration and foremost atrophy found in cognitively normal individuals suggests the role of BACE1 in neurodegeneration.
    origins: Vergallo, A., Lemercier, P., Cavedo, E., Lista, S., Vanmechelen, E., De Vos, A., ... & Alzheimer Precision Medicine Initiative. Plasma β-secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD. _Alzheimer's & dementia: the journal of the Alzheimer's Association_. Freeman Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Originals" are owned by Mets Medical and are not reproduced by any media, website or individual without authorization, and are authorized to be reproduced with the words "Source: Mets Medicine".
    all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
    at the same time reproduced content does not represent the position of this site.
    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.